Title of article
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Author/Authors
G Comi، نويسنده , , pulizzi، N نويسنده Department of Endocrinology and Metabolism pulizzi, N , M Rovaris، نويسنده , , O Abramsky، نويسنده , , T Arbizu، نويسنده , , A Boiko، نويسنده , , R Gold، نويسنده , , E Havrdova، نويسنده , , Samuel Komoly، نويسنده , , KW Selmaj، نويسنده , , B Sharrack، نويسنده , , M Filippi، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
8
From page
2085
To page
2092
Abstract
Background
A 24-week phase II trial has shown that 0•3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions. We assessed the effect of oral daily 0•3 and 0•6 mg
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
593048
Link To Document